In vitro activity of tigecycline and comparators against organisms associated with intra-abdominal infections collected as part of TEST (2004-2009)

Diagnostic Microbiology and Infectious Disease

Volumn 74, Issue 2, 2012, Pages 151-157

  Mayne, Donna ^a   Dowzicky, Michael J ^b  

^a Sacred Heart Hospital Pensacola   (United States)

^b PFIZER INC   (United States)

Author keywords

Antimicrobial resistance; Intra abdominal infections; Surveillance; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CLINDAMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MINOCYCLINE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ABDOMINAL INFECTION; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANAEROCOCCUS PREVOTII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; BROTH DILUTION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; ENTEROBACTER; ENZYME SYNTHESIS; ESCHERICHIA COLI; FINEGOLDIA MAGNA; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARVIMONAS MICRA; PEPTONIPHILUS; PEPTOSTREPTOCOCCUS ANAEROBIUS; PREVOTELLA BIVIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS;

ANTI-BACTERIAL AGENTS; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INTRAABDOMINAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 84866174585     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.05.032     Document Type: Article

References (18)

1. Blot S., De Waele J.J. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005, 65:1611-1620.
2. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eighth edition, M7-A8 2009, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standard for antimicrobial susceptibility testing: 20th informational supplement (M100-S20) 2010, CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standard for antimicrobial susceptibility testing: 20th informational supplement (June 2010 Update) (M100-S20-U) 2010, CLSI, Wayne, PA.
5. Dupont H. The empiric treatment of nosocomial intra-abdominal infections. Int J Infect Dis 2007, 11(Suppl 1):S1-S6.
6. Dowzicky M.J., Chmelařová E. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009. Int J Antimicrob Agents 2011, 37:562-566.
7. Fomin P., Koalov S., Cooper A., Babinchak T., Dartois N., De Vane N., et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience. J Chemother 2008, 20(Suppl 1):12-19.
8. Hawser S., Hoban D., Bouchillon S., Badal R., Carmeli Y., Hawkey P. Antimicrobial susceptibility of intra-abdominal Gram-negative bacilli from Europe: SMART Europe 2008. Eur J Clin Microbiol Infect Dis 2011, 30:173-179.
9. Mazuski J.E. Antimicrobial treatment for intra-abdominal infections. Expert Opin Pharmacother 2007, 8:2933-2945.
10. Nicolau D.P. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opin Pharmacother 2009, 10:1213-1222.
11. Nicoletti G., Nicolosi D., Rossolini G.M., Stefani S. Intra-abdominal infections: etiology, epidemiology, microbiological diagnosis and antibiotic resistance. J Chemother 2009, 21(Suppl 1):5-11.
12. Pfizer Inc (Wyeth Pharmaceuticals). Tygacil product insert. Philadelphia, Pennsylvania. Last Revised January 2011. Available from: Accessed May 18, 2011. http://www.pfizerpro.com/hcp/tygacil.
13. Reygaert W.C. Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline. Ther Clin Risk Manag 2010, 6:419-430.
14. Sartelli M. A focus on intra-abdominal infections. World J Emerg Surg 2010, 5:9-28.
15. Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J., Baron E.J., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Inf Dis 2010, 50:133-164.
16. Tellado J.M., Wilson S.E. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Surg Infect (Larchmt) 2005, 6:329-343.
17. Towfigh S., Pasternak J., Poirier A., Leister H., Babinchak T. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect 2010, 16:1274-1281.
18. Weigelt J.A. Empiric treatment options in the management of complicated intra-abdominal infections. Cleve Clin J Med 2007, 74:S29-S37.